NCT07258147 is a Phase 2 clinical trial of Immunotherapy in Lung Cancer (SCLC), sponsored by Sichuan University.

Who is sponsoring NCT07258147?

NCT07258147 is sponsored by Sichuan University.

What drugs are being tested in NCT07258147?

Interventions in NCT07258147: Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation, Stereotactic Body Radiation Therapy (SBRT).

What condition does NCT07258147 study?

NCT07258147 studies Lung Cancer (SCLC).

Is NCT07258147 still recruiting?

NCT07258147 is currently not yet recruiting. Last updated 2 December 2025.

Last reviewed 2025-12-02 · How we verify

NCT07258147

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Not yet recruiting Phase 2 Last updated 2 December 2025

What this trial tests

Phase 2 trial testing Immunotherapy in Lung Cancer (SCLC) in 30 participants. Not yet recruiting.

Timeline

25 December 2025

Primary endpoint
31 December 2027

30 December 2028

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	25 December 2025
Primary completion	31 December 2027
Estimated completion	30 December 2028
Sites	1 location across China

Drugs / interventions tested

Immunotherapy — full drug profile →
Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin) — full drug profile →
low-dose radiation
Stereotactic Body Radiation Therapy (SBRT) — full drug profile →

Conditions studied

Lung Cancer (SCLC) — all drugs for Lung Cancer (SCLC) →

Sponsor

Sichuan University

Who can join

Adults 18 to 75, any sex, with Lung Cancer (SCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is clinical trial evaluating the safety and efficacy of radiotherapy combined with immunotherapy and chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) and liver metastases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Immunotherapy

Trials testing the same drug.

NCT07293247 — A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After · Phase 2 · not yet recruiting
NCT07259473 — Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma · Phase 2 · not yet recruiting
NCT07297030 — SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer · Phase 2 · not yet recruiting
NCT07231575 — Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC · Phase 2 · not yet recruiting
NCT07062055 — BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases · Phase 2 · recruiting

Other recruiting trials for Lung Cancer (SCLC)

Currently open trials in the same condition.

NCT07202260 — Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung · active not recruiting

Other Sichuan University trials

Trials by the same sponsor.

NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
NCT07211009 — Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Tria · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07258147 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan University
Last refreshed: 2 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07258147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing